Property Name |
Property Value |
Unit |
Raw Value |
Raw Unit |
Annotation |
Factor |
Reference |
Absorption |
100.0 |
% |
~100 |
% |
PO, oral; |
|
DRUGBANK |
Absorption |
100.0 |
% |
~100 |
% |
IM,intramuscular injection; |
|
DRUGBANK |
Bioavailability |
75.0 |
% |
75.0 |
% |
PO, oral; |
|
DRUGBANK |
Bioavailability |
77.0 |
% |
77.0 |
% |
Rectal Administration; |
|
DRUGBANK |
Bioavailability |
72.5 |
% |
70-75 |
% |
PO, oral; |
|
The Pharmacological Basis of Therapeutics |
C Max |
300.0 |
ng/ml |
300.0 |
ug/L |
Oral single dose; |
|
DRUGBANK |
C Max |
348.0 |
ng/ml |
348.0 |
ug/L |
Oral multiple dose; |
|
DRUGBANK |
C Max |
166.0 |
ng/ml |
166.0 |
ug/L |
IM,intramuscular injection; |
|
DRUGBANK |
C Max |
294.0 |
ng/ml |
294.0 |
ug/L |
Rectal Administration; |
|
DRUGBANK |
C Max |
592.0 |
ng/ml |
592±178 |
ng/ml |
Tablet, PO, oral; immediate release formulation; |
|
The Pharmacological Basis of Therapeutics |
C Max |
110.0 |
ng/ml |
110±32 |
ng/ml |
Tablet, PO, oral; Active metabolite; immediate release formulation; |
|
The Pharmacological Basis of Therapeutics |
T Max |
2.5 |
h |
2-3 |
h |
PO, oral; |
|
DRUGBANK |
T Max |
1.8 |
h |
1.6-1.9 |
h |
Oral single dose; |
|
DRUGBANK |
T Max |
0.75 |
h |
0.75 |
h |
IM,intramuscular injection; |
|
DRUGBANK |
T Max |
3.3 |
h |
3.3 |
h |
Rectal Administration; |
|
DRUGBANK |
T Max |
2.3 |
h |
2.3±1.4 |
h |
Tablet, PO, oral; immediate release formulation; |
|
The Pharmacological Basis of Therapeutics |
T Max |
2.4 |
h |
2.4±1.1 |
h |
Tablet, PO, oral; Active metabolite; immediate release formulation; |
|
The Pharmacological Basis of Therapeutics |
Tss |
48.0 |
h |
2.0 |
day |
Oral single dose; |
|
DRUGBANK |
Metabolic |
92.5 |
% |
90-95 |
% |
Liver metabolism; Caucasian; |
|
DRUGBANK |
Metabolic |
7.5 |
% |
5-10 |
% |
Liver metabolism; poor metabolizers, PM; |
|
DRUGBANK |
Clearance |
0.22 |
L/h/kg |
3.73 |
ml/min/kg |
RD, renal impairment, Renal disease,including uremia; patients; |
|
DRUGBANK |
Clearance |
0.51 |
L/h/kg |
8.5 |
ml/min/kg |
normal,healthy; adults; |
|
DRUGBANK |
Clearance |
0.48 |
L/h/kg |
8(6-12) |
ml/min/kg |
|
hepatopathy,LD ↓ ;RD, renal impairment, Renal disease,including uremia ↓ ; |
The Pharmacological Basis of Therapeutics |
Clearance |
0.39 |
L/h/kg |
6.5 |
ml/min/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Volume of Distribution |
2.8 |
L/kg |
2.6-2.9 |
L/kg |
|
|
DRUGBANK |
Volume of Distribution |
306.0 |
L |
306.0 |
L |
Total volume of distribution; PO, oral; |
|
DRUGBANK |
Volume of Distribution |
203.0 |
L |
203.0 |
L |
Total volume of distribution; parenteral administration; |
|
DRUGBANK |
Volume of Distribution |
2.7 |
L/kg |
2.7(2.3-3.9) |
L/kg |
|
|
The Pharmacological Basis of Therapeutics |
Volume of Distribution |
2.8 |
L/kg |
2.8 |
L/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Half-life |
5.5 |
h |
5-6 |
h |
|
|
DRUGBANK |
Half-life |
8.0 |
h |
8 |
h |
Metabolite; |
|
DRUGBANK |
Half-life |
5.5 |
h |
5.5(4.5-7.5) |
h |
|
RD, renal impairment, Renal disease,including uremia ↑ ;chronic liver disease ↑ ; |
The Pharmacological Basis of Therapeutics |
Half-life |
5.8 |
h |
5.8 |
h |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Toxicity LD50 |
350.0 |
mg/kg |
350.0 |
mg/kg |
PO, oral; mouse; |
|
DRUGBANK |
Toxicity LD50 |
325.0 |
mg/kg |
300-350 |
mg/kg |
PO, oral; Rattus, Rat; |
|
T3DB |
Eliminate Route |
30.0 |
% |
~30 |
% |
Urinary excretion; Unchanged drug; |
|
DRUGBANK |
Eliminate Route |
20.0 |
% |
10-30 |
% |
Urinary excretion; PO, oral; Unchanged drug; |
|
The Pharmacological Basis of Therapeutics |
Protein Binding |
20.0 |
% |
~20 |
% |
plasma proteins; |
|
DRUGBANK |
Protein Binding |
20.0 |
% |
20 |
% |
|
|
The Pharmacological Basis of Therapeutics |